Tumor Board: Evolving Immunotherapy Strategies for Stage I-III NSCLC

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Tina Cascone, MD, PhD;Puneeth Iyengar, MD, PhD; and Paula A. Ugalde Figueroa, MD; discuss evolving immunotherapy strategies for stage I to III non–small cell lung cancer (NSCLC), spanning surgical work-up and the shifting definition of resectability, perioperative immunotherapy trial data, the way that pathologic response guides treatment decisions, and the integration of radiation with immunotherapy in unresectable disease.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Evaluate contemporary clinical trial evidence supporting immunotherapy across stages I to III NSCLC
• Incorporate multidisciplinary assessment and molecular/biologic features into evidence-based, individualized treatment decisions for patients with resectable and unresectable early-stage NSCLC
• Apply best practices for mitigating and managing immune-related adverse effects in patients with early-stage NSCLC

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals.

Chair:

Tina Cascone, MD, PhD

Associate Professor
Multidisciplinary Section Chief and Director of Translational Research
Department of Thoracic/Head and Neck Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: ASCO Post, AstraZeneca, Bio Ascend, Bristol Myers Squibb, Daiichi Sankyo, Genentech, IDEOlogy Health, Merck, Nuvalent, oNKo-innate, Pfizer, RAPT Therapeutics, Summit Therapeutics; Institutional Grant/Research Support: AstraZeneca, Bristol Myers Squibb, Merck

Faculty:

Puneeth Iyengar, MD, PhD

Radiation Oncologist
Director, Metastatic Program
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AstraZeneca, Johnson & Johnson, Novocure, Pfizer; Grant/Research Funding: Incyte

Paula A. Ugalde Figueroa, MD

Associate Professor of Surgery
Co-director, Continuing Medical Education
Harvard Medical School
Associate Thoracic Surgeon
Canepari Family Endowed Chair in Thoracic Surgery
Brigham and Women’s Hospital
Dana-Farber Cancer Institute
Boston, MA

Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AstraZeneca, Medtronic/Covidien.

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including information on surgical resectability, perioperative immunotherapy, biomarker-guided treatment, and radiation strategies, go to https://www.gotoper.com/courses/tumor-board-evolving-immunotherapy-strategies-for-stage-i-iii-nsclc-1.

Release Date

July 20, 2026

Expiration Date

July 20, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.